A study published has revealed for the first time the mechanism responsible for blood clot arising from thrombosis with thrombocytopenia syndrome (TTS) following vaccination with AstraZeneca vaccine. A multi-institutional study published on December 1 in the journal Science Advances has revealed for the first time the mechanism responsible for blood clot arising from thrombosis with … Continue reading Mechanism of blood clots after Oxford vaccine administration found
Oxford University vaccine ChAdOx1 nCoV-19
Serum’s supply to COVAX hit by India’s poor vaccination planning
While India approved Rs.3,000 crore in funding to Serum to meet the cost of ramping up production capacity only on April 19, 2021, Serum had received $300 million funding in August and September 2020 from the Gates Foundation to supply 200 million doses by first half of 2021. But only a paltry 19.8 million doses … Continue reading Serum’s supply to COVAX hit by India’s poor vaccination planning
Serum refuses to address differential pricing for Central and State governments
The differential pricing for central and State governments is the sticking point, which is not addressed by Serum in its statement that came after the Health Minister and Health Ministry clarified the price of Rs.150 per dose to the central government. On April 24, Adar Poonawalla, CEO of Serum Institute, issued a statement to address … Continue reading Serum refuses to address differential pricing for Central and State governments
Will adenovirus antibodies reduce the efficacy of vector vaccines?
While it is unclear if pre-existing antibodies to adenovirus vector will affect vaccine efficacy, it is possible that repeated vaccination using adenovirus-based vaccine either as a booster or as annual vaccination, if the need arises, will result in reduced efficacy due to vector immunity.
Oxford vaccine is protective against the U.K. variant, preprint says
The Oxford vaccine appears to protect people against the new, more transmissible variant (B.1.1.7) first found in Britain in end-November and has since become the dominant one in the U.K. The efficacy of the vaccine against the U.K. variant is comparable with the efficacy against other SARS-CoV-2 virus lineages. The Oxford vaccine appears to protect … Continue reading Oxford vaccine is protective against the U.K. variant, preprint says
Updated efficacy results underline the benefits of delaying second dose of Oxford vaccine
The preprint shows that Oxford vaccine efficacy was high when the interval between the two doses was two months and continued to increase with a longer dose interval. Vaccine efficacy after two standard doses increased from 54.9% when the gap between the two doses was less than six weeks to 82.4% when the gap between … Continue reading Updated efficacy results underline the benefits of delaying second dose of Oxford vaccine
Reneging on the ‘no-profit pledge’ to supply Oxford vaccine
After promising on multiple occasions that Oxford vaccine will be provided on a not-for-profit basis for the duration of the pandemic across the world, and in perpetuity to low- and middle-income countries, AstraZeneca came up with riders while signing an agreement with Brazil. And Serum Institute has been brazenly violating the spirit of the agreement … Continue reading Reneging on the ‘no-profit pledge’ to supply Oxford vaccine
Serious violations in Covaxin trial in Bhopal show nothing has changed since the egregious HPV vaccine trial
The Covaxin phase-3 clinical trial in Bhopal shows that nothing much has changed even more than a decade since the highly controversial HPV vaccine trial in Andhra Pradesh wherein 23,500 girls were vaccinated without a proper informed consent. There is evidence that the trial in Bhopal has serious ethical violations of informed consent and medical … Continue reading Serious violations in Covaxin trial in Bhopal show nothing has changed since the egregious HPV vaccine trial
With hasty approval, India squanders an opportunity to build trust in COVID-19 vaccine
With the approval to Covaxin even in the absence of efficacy data, the Indian regulator has joined the ranks of China and Russia. What good is a vaccine that is safe but the efficacy is unknown. Transparency in the approval process is vital for gaining the trust of people to avoid vaccine hesitancy and increase … Continue reading With hasty approval, India squanders an opportunity to build trust in COVID-19 vaccine
Why people with prior SARS-CoV-2 infection still need to be vaccinated
A small minority of those with even symptomatic infection do not end up making high levels of antibodies, and another small minority of such naturally infected people do not make long-lasting antibodies. So, all in all, it is the easiest policy to immunise people without worrying about whether they have been previously infected or not. … Continue reading Why people with prior SARS-CoV-2 infection still need to be vaccinated
Science Chronicle 